Aki Shiozawa

List of Publications by Year
in descending order

19	398	932766 10	794141 19
papers	citations	h-index	g-index

20	20	20	614
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review. Journal of Rheumatology, 2017, 44, 388-396.	1.0	111
2	Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis Research and Therapy, 2015, 17, 120.	1.6	52
3	An assessment of the impact of pregnancy on trauma mortality. Surgery, 2011, 149, 94-98.	1.0	35
4	Cost of Inpatient Care and its Association with Hospital Competition. Journal of the American College of Surgeons, 2011, 212, 12-19.	0.2	32
5	Physician Adherence to ACR Gout Treatment Guidelines: Perception Versus Practice. Postgraduate Medicine, 2014, 126, 257-267.	0.9	28
6	Health-related quality of life and treatment satisfaction in patients with gout: results from a cross-sectional study in a managed care setting. Patient Preference and Adherence, 2015, 9, 971.	0.8	24
7	Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: a retrospective medical claims-based analysis. BMJ Open, 2015, 5, e007214.	0.8	22
8	Achieving Serum Urate Goal: A Comparative Effectiveness Study between Allopurinol and Febuxostat. Postgraduate Medicine, 2014, 126, 65-75.	0.9	20
9	Serum uric acid levels and the risk of flares among gout patients in a US managed care setting. Current Medical Research and Opinion, 2017, 33, 117-124.	0.9	18
10	A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database. Journal of Clinical Rheumatology, 2015, 21, 411-418.	0.5	11
11	Febuxostat in the management of gout: a cost-effectiveness analysis. Journal of Medical Economics, 2016, 19, 265-276.	1.0	9
12	Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States. Neurourology and Urodynamics, 2020, 39, 2206-2222.	0.8	8
13	The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective. Clinical Therapeutics, 2016, 38, 1710-1725.	1.1	6
14	Treatment and comorbidities of multiple sclerosis in an employed population in Japan: analysis of health claims data. Neurodegenerative Disease Management, 2018, 8, 97-103.	1.2	5
15	Higher Resource Utilization and Costs in Long-Term Nursing Home Residents With Overactive Bladder: A Retrospective Study of Medicare Beneficiaries. Journal of the American Medical Directors Association, 2021, 22, 1300-1306.	1.2	5
16	A 12-Year Retrospective Study of the Prevalence of Anticholinergic Polypharmacy and Associated Outcomes Among Medicare Patients with Overactive Bladder in the USA. Drugs and Aging, 2021, 38, 1075-1085.	1.3	5
17	Real-world treatment patterns of gout patients treated with colchicine or other common treatments for gout in acute care settings: a retrospective chart review study. Current Medical Research and Opinion, 2015, 31, 1611-1620.	0.9	2
18	Increased Healthcare Resource Utilization and Direct and Indirect Costs in Patients with Depression and Comorbid Overactive Bladder: Evidence From a Retrospective, Matched Caseâ€“Control Cohort Analysis. Advances in Therapy, 2020, 37, 4599-4613.	1.3	2

#	Article	IF	Citations
19	Cost-effectiveness model for a hypothetical monotherapy vs standard of care in adult patients with treatment-resistant depression . ClinicoEconomics and Outcomes Research, 2019, Volume 11, 257-270.	0.7	1